调脂汤对稳定型心绞痛患者临床疗效及Lp（a）、MMP-9、IMT的影响
|
摘要
目的:本课题旨在观察调脂汤对冠心病稳定型心绞痛(痰阻心脉证)患者的临床疗效及LP(a)、MMP-9、IMT的影响,初步评价其临床疗效、安全性及有效性,并探讨其部分作用机制。
方法:将冠心病稳定型心绞痛(痰阻心脉)患者60例分为治疗组(调脂汤)组30例,对照组(辛伐他汀)组30例。治疗组给予调脂汤,对照组给予辛伐他汀,疗程2个月。观察对比治疗前后心绞痛发作次数、持续时间;心电图;中医症候积分;血清基质金属蛋白酶9浓度;颈动脉内膜中层厚度;TC、TG、LDL-C、HDL-C、Lp(a)水平和血、尿常规;血糖和肝肾功能。
结果:
1.经过治疗后两组患者病情都有明显改善,治疗组与对照组疗效相比无显著性差异(P>0.05)。治疗组患者心绞痛疗效、心电图疗效分别为96.67%、93.33%优于对照组93.33%、90.00%。
2.在中医症候指征(胸痛、胸闷、心悸、乏力、自汗)方面,两药物均有显著的效果(P<0.01),调脂汤组略有优势,但无统计学意义(P>0.05)。
3.两组药物可以显著降低血清总胆固醇、低密度脂蛋白及甘油三酯水平(P<0.01)。但两组之间差别较小,无统计学意义(P>0.05)。
4.血清基质金属蛋白酶9浓度,明显下降(P<0.01),彩色多普勒超声显示颈动脉内中膜厚度、斑块积分均有一定程度的下降,组间差异没有统计学意义(P>0.05)。脂蛋白A水平在治疗组有一定程度的下降而在对照组无明显变化。组间差异有统计学意义(P<0.01)。
5.两组治疗前后生命体征平稳,治疗前后血、尿常规和肝、肾功能等各项指标差异无统计学意义(P>0.05)。
结论:
1.调脂汤可以改善冠心病稳定型心绞痛患者的临床症状,减少心绞痛发病次数,持续时间及中医症候指征积分。
2.调脂汤可以降低冠心病稳定型心绞痛患者血清脂蛋白A及基质金属蛋白酶-9水平。
3.调脂汤可以降低颈动脉内膜厚度,在一定程度上阻止动脉粥样硬化病变的进展。
Objective:To study the efficacy and saftety of tiaozhi decoction, treating stable angina patients of(the congealing phlegm of heart vessels)and impact of LP(a)、MMP-9、IMT, discuss a preliminary evaluation of its safety and effectiveness and part of its clinical mechanism.
Methods:selected a total of 60 angina pectoris patients with the syndrome of the congealing phlegm ofheart vessels.were divided into two groups. The treatment group had 30 patiens who were given Tiaozhi decoction,The control group had 30 patiens who were given simvastatin.All the patiens were treated with two months. Cure and effictive rates in the two groups were evaluated .Duration of angina attack and ferquence were counted and measured; ECG; TCM; serum MMP-9、carotid artery IMT; TC,LDL-C,HDL-C,TG, Lp(a),Glucose, were measured regularly before study entry and close to the study respectively.
Results:
1.After treatment ,two groups of patients there has been a marked improvement,and in the treatment group compared with control group there was no significance difference(P>0.05).The treatment group with syptoms of angina、ECG effective rates were 96.67%、93.33% better than the control group93.33%、90.00%.
2.TCM symptoms and signs such as chest pain, chest constriction, palpitation, breath shortness, fatigue,spontaneous perspiration were ameliorated significantly in both groups (P<0.01). No differents between two groups (P>0.05).
3.The levels of CH,LDL,TG in both groups were lowered markedly (P<0.01) .But there have no difference between the two groups(P>0.05).
4. The level of serum MMP-9 were lowered as compared with before treatment,indicating significantly differences(P<0.01); The carotid IMT and plaque score in both groups trended to decrease at the end of the study.There have no differents between two groups (P>0.05);The leve of lp(a) in the treatmen group trended to decrease at the end of the study,but in the control group did not, The treatmen group is superior to the control group(P<0.01). 5. No changes were found at at pre-and post-treatment in safety indexes of the both groups ,like routine tests of blood and urine hepatic function and renal function.
Conclusion:
1.Tiaozhi decoction can improved clinical symptoms of stable angina pectoris, decrease angina attack and frequency and TCM.
2. Tiaozhi decoction can decrease the level of serum MMP-9 and Lp(a) in stable angina patients.
3. Tiaozhi decoction can decrease carotid artery IMT, On a certain degree to prevent AS.
方法:将冠心病稳定型心绞痛(痰阻心脉)患者60例分为治疗组(调脂汤)组30例,对照组(辛伐他汀)组30例。治疗组给予调脂汤,对照组给予辛伐他汀,疗程2个月。观察对比治疗前后心绞痛发作次数、持续时间;心电图;中医症候积分;血清基质金属蛋白酶9浓度;颈动脉内膜中层厚度;TC、TG、LDL-C、HDL-C、Lp(a)水平和血、尿常规;血糖和肝肾功能。
结果:
1.经过治疗后两组患者病情都有明显改善,治疗组与对照组疗效相比无显著性差异(P>0.05)。治疗组患者心绞痛疗效、心电图疗效分别为96.67%、93.33%优于对照组93.33%、90.00%。
2.在中医症候指征(胸痛、胸闷、心悸、乏力、自汗)方面,两药物均有显著的效果(P<0.01),调脂汤组略有优势,但无统计学意义(P>0.05)。
3.两组药物可以显著降低血清总胆固醇、低密度脂蛋白及甘油三酯水平(P<0.01)。但两组之间差别较小,无统计学意义(P>0.05)。
4.血清基质金属蛋白酶9浓度,明显下降(P<0.01),彩色多普勒超声显示颈动脉内中膜厚度、斑块积分均有一定程度的下降,组间差异没有统计学意义(P>0.05)。脂蛋白A水平在治疗组有一定程度的下降而在对照组无明显变化。组间差异有统计学意义(P<0.01)。
5.两组治疗前后生命体征平稳,治疗前后血、尿常规和肝、肾功能等各项指标差异无统计学意义(P>0.05)。
结论:
1.调脂汤可以改善冠心病稳定型心绞痛患者的临床症状,减少心绞痛发病次数,持续时间及中医症候指征积分。
2.调脂汤可以降低冠心病稳定型心绞痛患者血清脂蛋白A及基质金属蛋白酶-9水平。
3.调脂汤可以降低颈动脉内膜厚度,在一定程度上阻止动脉粥样硬化病变的进展。
Objective:To study the efficacy and saftety of tiaozhi decoction, treating stable angina patients of(the congealing phlegm of heart vessels)and impact of LP(a)、MMP-9、IMT, discuss a preliminary evaluation of its safety and effectiveness and part of its clinical mechanism.
Methods:selected a total of 60 angina pectoris patients with the syndrome of the congealing phlegm ofheart vessels.were divided into two groups. The treatment group had 30 patiens who were given Tiaozhi decoction,The control group had 30 patiens who were given simvastatin.All the patiens were treated with two months. Cure and effictive rates in the two groups were evaluated .Duration of angina attack and ferquence were counted and measured; ECG; TCM; serum MMP-9、carotid artery IMT; TC,LDL-C,HDL-C,TG, Lp(a),Glucose, were measured regularly before study entry and close to the study respectively.
Results:
1.After treatment ,two groups of patients there has been a marked improvement,and in the treatment group compared with control group there was no significance difference(P>0.05).The treatment group with syptoms of angina、ECG effective rates were 96.67%、93.33% better than the control group93.33%、90.00%.
2.TCM symptoms and signs such as chest pain, chest constriction, palpitation, breath shortness, fatigue,spontaneous perspiration were ameliorated significantly in both groups (P<0.01). No differents between two groups (P>0.05).
3.The levels of CH,LDL,TG in both groups were lowered markedly (P<0.01) .But there have no difference between the two groups(P>0.05).
4. The level of serum MMP-9 were lowered as compared with before treatment,indicating significantly differences(P<0.01); The carotid IMT and plaque score in both groups trended to decrease at the end of the study.There have no differents between two groups (P>0.05);The leve of lp(a) in the treatmen group trended to decrease at the end of the study,but in the control group did not, The treatmen group is superior to the control group(P<0.01). 5. No changes were found at at pre-and post-treatment in safety indexes of the both groups ,like routine tests of blood and urine hepatic function and renal function.
Conclusion:
1.Tiaozhi decoction can improved clinical symptoms of stable angina pectoris, decrease angina attack and frequency and TCM.
2. Tiaozhi decoction can decrease the level of serum MMP-9 and Lp(a) in stable angina patients.
3. Tiaozhi decoction can decrease carotid artery IMT, On a certain degree to prevent AS.
引文
[1]金钊,姜冬云,宋兴.从脾胃论治冠心病[J].四川中医杂志,2009,27(10),27-28
[2]赵喜娟李振军.张荣新主任医师治疗冠心病心绞痛经验举隅[J].陕西中医学院学报2006,29(1):19
[3]梅岩,张明雪.从“阳微阴弦”治冠心病[J].中医药学刊,2006,24(4):683-684.
[4]李敬孝,韩超,焦赢君.从痰论治冠心病[J].长春中医药大学学报,2009,25(5):685-686
[5]林宝华.浅谈冠心病心绞痛从肝论治[J].福建中医药2006,37(3):34-35
[6]张明雪,常艳鹏,吴东宁等.论“气滞”在冠心病发病中的作用[J].世界中西医结合杂志,2009,4(7):486-487
[7]李成林,王庆高,朱智德.冠心病心绞痛中医证型与脑钠肽、C-反应蛋白和肌钙蛋白相关性研究[J].新中医,2008,40(7):32-33.
[8]黄永生.冠心病心绞痛临床诊治体会[J].长春中医学院学报,2005,21(1):16
[9]王振涛,韩丽华,朱照军等.孙建芝辨证冠心病经验[J].江苏中医药,2009,41(4):15-16
[10]王阶,邢雁伟,姚魁武,李军.冠心病心绞痛中医证候要素研究及临床应用[J].湖北中医学院学报,2009,11(3):3-5
[11]张浒,莫健平,林仕群.血府逐瘀汤加曲美他嗪治疗冠状动脉粥样硬化性心脏病心绞痛43例疗效分析[J].河北医药,2009,31(13):1663-1664
[12]张云.川芎嗪注射液治疗冠心病心绞痛疗效观察[J].中华中西医学杂志,2009,7(2):65-65
[13]陈琼莉.丹红注射液治疗老年性冠心病心绞痛56例疗效观察[J].中华实用中西医杂志2009,22(19):1521
[14]杨立群,李春瑜.活血化痰法治疗冠心病心绞痛[J].中国现代药物应用,2009,3(13):111-112
[15]齐双,刘东方.调脂汤治疗稳定性心绞痛临床观察.黑龙江中医药学报,2009,37(4)42-44
[16]谭奇,刘建和.益气活血法治疗冠心病心绞痛62例临床观察[J].中华临床医学研究杂志,2007,13(5):655-656
[17]唐善平.益气活血法对老年不稳定型心绞痛患者左室收缩功能的影响[J].中国中医急症学,2009,18(9):1403-1404
[18]史春远.益气活血方治疗冠心病60例[J].中国医学创新,2009,6(27):143
[19]刘金先.理气化瘀解毒法治疗冠心病106例[J].中医药临床杂志,2009,21(1):5
[20]颜君.疏肝理气发治疗冠心病心绞痛(附66例临床分析)[J].中外医疗,2009,12:113
[21]欧阳真理.益气温阳宣痹通络法治疗心绞痛60例[J].深圳中西医结合杂志,2006,16(1):49
[22]孟兆君,王海霞,房泽岱.宣痹通阳行气活血法治疗冠心病心绞痛临床观察[J].中国中医急症,2007,16(2):130-131
[23]施敖听.益气养阴法为主治疗冠心病56例[J].实用中医内科杂志,2005,19(2):159
[24]李景鹤.养阴益气活血方治疗冠心病[J].河南中医,2007,27(11):43
[25]卫生部.2007年中国卫生统计年鉴.北京中国医科协和大学出版社,2007
[26]卫生部心血管病防治研究中心.中国心血管病报告2007.中国大百科全书出版社,2007
[27] M Sawabe.et al. High lipoprotein(a) level promotes both coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases. Heart, 2009, 95:1997-2002
[28] Anna Bennet, PhD; Emanuele Di Angelantonio, MD, MSc; Sebhat Erqou, MD, M Ph il; et al. Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease . Arch Intern Med, 2008, 168(6):598-608.
[29] Erqou S, Kaptoge S, Perry PL, Di Angelantonio E Thompson A, White IR, et al. Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease,Stroke, and Nonvascular Mortality JAMA, 2009, 302(4):412- 423.
[30] Pia R. Kamstrup.et al. Pentanucleotide Repeat Polymorphism, Lipoprotein(a)Levels, and Risk of Ischemic Heart Disease. Journal of Clinical Endocrinology & Metabolism, 2008, 93: 3769-3776
[31] Rebecca J. Sharp.et al. Structural features of apolipoprotein B synthetic peptides that inhibitlipoprotein(a) assembly. Journal of Lipid Research,2004,45 : 2227-2234,
[32] Tsimikas, Sotirios. Witztum, Joseph.et al .The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Hyperlipidaemia and cardiovascular disease, 2008, 19( 4) :369-377
[33] Sotirios Tsimikas, M.D .et al. Oxidized Phospholipids. Lp(a) Lipoprotein, and Corona -ry Artery Disease . the New England Journal of Medicine, 2005, 353:46-57
[34] Robert Clarke, F.R.C.P., John F. Peden, Ph.D., Jemma C. Hopewell, Ph.D., Theodosios Kyriakou Ph.D. et.al. Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease, The NEW ENGLAND JOURANLofWEDICINE, 2009, 26, 361: 25182528.
[35] Mark W.et al. FeinbergTransforming Growth Factor-β1 Inhibition of Vascular Smo oth Muscle Cell Activation Is Mediated via Smad3.The Journal of Biological Chemis–try, 2004, 279: 16388-16393.
[36] Shirling Tsai. et al. TGF-βthrough Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation . Am J Physiol Heart Circ Physiol, 2009, 297:0363-6135
[37] William Discepolo.et al. Lipoprotein(a) and Thrombocytes: Potential Mechanisms Underlying Cardiovascular Risk. Pathophysiol Haemos Thromb,2006, 35:314-321
[38] Konrad Schmidt. et al.Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon. European Journal of Human Genetics, 2006, 14: 190–201.
[39] Erdembileg Anuurad.et al. High Levels of Inflammatory Biomarkers Are Associated with Increased Allele-Specific Apolipoprotein(a) Levels in African-Americans .The Journal of Clinical Endocrinology& Metabolism, 2008,93( 4) : 1482-1488
[40] Andrew C. Newby, Jason L. Johnson.et al. Genetic Strategies to Elucidate the Roles of Matrix Metalloproteinases in Atherosclerotic Plaque Growth andStability.Circulati -on Research, 2005, 97:958.
[41] Newby AC. et al. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atheros clerotic plaque rupture〔J〕. Physiol Rev,2005,85(1): 1-31
[42] Chow AK,Cena J,Schulz R. Acute actions and novel targets of matrix metallo pro teinases in the heart and vasculature〔J〕.Br J Pharmacol,2007,152(2):189-205.
[43] Kuge Y,Takai N,Ishino S,et al. Distribution profiles of membrane type-1 matrix metalloproteinase (MT1 , MMP) , matrix metalloproteinase(MMP-2) and cyclooxygenase-2 (COX-2) in rabbit atherosclerosis:comparison with plaque instability analysis〔J〕. Biol Pharm Bull, 2007, 30(9):1634-40.
[44] Eve Pearce, David-Alexandre Tregouet, Ann Samneg?rd, et al. Haplotype Effect of the Matrix Metalloproteinase-1 Gene on Risk of Myocardial Infarction. Circ. Res, 2005, 97: 1070-1076
[45] Manginas A , Bei E , Chaidaroglou A,et al. Peripheral levels of matrix metalloproteinase-9 , interleukin-6 , and C-reactive protein are elevated in patients with acute coronary syndromes: Correlations with serum troponinI〔J〕.Clin Cardiol, 2005, 28(4):182-6.
[46] KeitaItatsu, MotokoSasaki, JunpeiYamaguchi, et al. Cyclooxygenase-2 Is Involved in the Up- Regulation of Matrix Metalloproteinase-9 in Cholangiocarcinoma Induced by Tumor Necrosis Factor-α. Am J Pathol, 2009,174(3): 829–841.
[47] Zhiwei Wang, Dejuan Kong, Sanjeev Banerjee, et al. Down-regulation of Platelet-Derived Growth Factor-D Inhibits Cell Growth and Angiogenesis through Inactivation of Notch-1 and Nuclear Factor- B Signaling .Cancer Res, 2007, 67(23):11377–85
[48] John Lamar, Vandana Iyer,and C. Michael DiPersio. Integrinα3β1 potentiates TGFβ- mediated induction of MMP-9 in immortalized keratinocytes. Journal ofInvestigative Dermatology, 2008, 128: 575–586
[49] Caroline Demacq, Ana P. de Souza, Alcyone A. Machado, Raquel F. Gerlach and Jose E. Tanus-Santos. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clinica Chimica Acta, 2006, 365: 183-187
[50] Nicholas L. Mills, M.D., H?kan T?rnqvist, M.D., Manuel C. Gonzalez, M.D., et al. Ischemic and Thrombotic Effects of Dilute Diesel-Exhaust Inhalation in Men with Coronary Heart Disease. The New England Journal of Medicine,2007,357:1075-1082
[51] Amie K. Lund, JoAnn Lucero, SelitáLucas, Michael C. Madden, Jacob D. et al. Vehicular Emissions Induce Vascular MMP-9 Expression and Activity Associated With Endothelin-1–Mediated Pathways. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29:511
[52] Welsh P, Whincup PH, Papacosta O, Wannamethee SG, Lennon L, Thomson A, Rumley A, Lowe GD. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. Oxford Journals Medicine,2008, 101(10):785-91.
[53] Buralli S, Dini FL, Ballo P, et al. Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am J Cardiol, 2010, 105(6):853-6.
[54] Deardorff R, Spinale FG. Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. Biomark Med, 2009, 3(5):513-523.
[55] Wald DS, Bestwick JP, Morton G, et al. Combining carotid intima-media thickness with carotid plaque on screening for coronary heart disease. Journal of Medical Screening, 2009, 16(3):155-9.
[56] Grewal J, Anand S, Islam S, Lonn E; SHARE and SHARE-AP Investigators Prevalence and predictors of subclinical atherosclerosisamong asymptomatic "low risk" individuals in a multiethnic population. Atherosclerosis, 2008 ,197(1): 435-42.
[57] Rohani M, Jogestrand T, Ekberg M, et al. Interrelation between the Extent of atherosclerosis in the thoracic aorta, carotidintima-media Thickness and the extent of coronary artery disease[J]. Atheroselerosis, 2005, 179(2): 311-316.
[58] Chien KL, Su TC, Jeng JS, et al. Carotid artery intima-media thickness, carotid plaque and coronary heart disease and stroke in Chinese. PLoS One, 2008,3(10): 34-35.
[59] Kwon TG, Kim KW, Park HW, Jeong JH, Kim KY, Bae JH. Prevalence and significance of carotid plaques in patients with coronary atherosclerosis. Korean Circ J, 2009, 39(8): 317-21.
[60] Strandberg TE, Pyorala K, Cook TJ, et al 4S Group. Mortality andIncidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) [J] Lancet , 2004, 364(9436):771-777.
[61] MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial [J]. Lancet, 2002, 3607-3622.
[62] Grundy SM, Cleeman J l, Merz CN, et al. National Heart,Lung,and blood Institut -e:American College of Cardiology Foundation:Ameri-can Heart Association. Implic-ations of recent clinical trials for theNational Cholesterol Edueation Program AdultTreatment PaneⅢguidelines[J]. Circulation, 2004,110(2):227-239.
[63] LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets(TNT) Investigato -rs . Intensive lipid lowering with atorvastatin in patients with stable coronary disease [J]. N Engl J Med, 2005, 352(14):1425-1435.
[64] Kolovou GD, Katerina A, Ioannis V, Cokkinos DV.Simvastatin: two decades in a circl -e. Cardiovasc Ther, 2008, 26(2): 166-78.
[65] Lo Prete AC, Dina CH, Azevedo CH, et al. In Vitro Simultaneous Transfer of Lipids to HDL in Coronary Artery Disease and in Statin Treatment. Lipids, 2009, 44: 917-924
[66] Saito Y.et al. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag, 2009, 5:921-36
[67] Barter PJ, Brandrup-Wognsen G, Palmer MK, Nocholls SJ. Effect of statins on HDL: a complex process unrelated to changes in LDL: Analysis of the VOYAGER Database. J Lipid Res, 2009, 5: 195-200
[68] Jia XW, Fu XH, Zhang J, et al. Inten -sive cholesterol lowering with statin improves the outcomes of percutaneous coronar -y intervention in patients with acute coronary syndrome. Chinese Medical Journal, 2009, 122(6):659-64
[69] Cakmak M, Tanriverdi H, Cakmak N, et al. Simvastatin may improve myocardial perfusion abnormality in slow coronary flow. Cardiology, 2008,110(1): 39-44
[70] Chan KC, Wang CJ, Ho HH, Chen HM, Huang CN.Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53. Pharmacol Res, 2008, 58(3-4): 247-56.
[71] Wada H, Abe M, Ono K, et al. Statins activate GATA-6 and induce differentiated vascular smooth muscle cells. Biochem Biophys Res Commun , 2008 ,374(4):731-6
[72] Park KW, Hwang KK, Cho HJ, et al. Simvastatin enhances endothelial differentiation of peripheral blood mononuclear cells in hypercholesterolemic patients and induces pro-angiogenic cytokine IL-8 secretion from monocytes. Clin Chim Acta, 2008, 388(1-2): 156-66.
[73] Obi C, Wysokinski W, Karnicki K, Owen WG, McBane RD 2nd. Inhibition of platelet -rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy. Arterioscler Thromb Vasc Biol,2009,29(9):1271-6.
[74] Arnaboldi L, Guzzetta M, Pazzucconi F, Radaelli G, Paoletti R, Sirtori CR, Corsini A. Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. Pharmacol Res, 2007, 56(6): 503-8
[75] Massonnet B, Normand S, Moschitz R, et al. Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human921-36
[67] Barter PJ, Brandrup-Wognsen G, Palmer MK, Nocholls SJ. Effect of statins on HDL: a complex process unrelated to changes in LDL: Analysis of the VOYAGER Database. J Lipid Res, 2009, 5: 195-200
[68] Jia XW, Fu XH, Zhang J, et al. Inten -sive cholesterol lowering with statin improves the outcomes of percutaneous coronar -y intervention in patients with acute coronary syndrome. Chinese Medical Journal, 2009, 122(6):659-64
[69] Cakmak M, Tanriverdi H, Cakmak N, et al. Simvastatin may improve myocardial perfusion abnormality in slow coronary flow. Cardiology, 2008,110(1): 39-44
[70] Chan KC, Wang CJ, Ho HH, Chen HM, Huang CN.Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53. Pharmacol Res, 2008, 58(3-4): 247-56.
[71] Wada H, Abe M, Ono K, et al. Statins activate GATA-6 and induce differentiated vascular smooth muscle cells. Biochem Biophys Res Commun , 2008 ,374(4):731-6
[72] Park KW, Hwang KK, Cho HJ, et al. Simvastatin enhances endothelial differentiation of peripheral blood mononuclear cells in hypercholesterolemic patients and induces pro-angiogenic cytokine IL-8 secretion from monocytes. Clin Chim Acta, 2008, 388(1-2): 156-66.
[73] Obi C, Wysokinski W, Karnicki K, Owen WG, McBane RD 2nd. Inhibition of platelet -rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy. Arterioscler Thromb Vasc Biol,2009,29(9):1271-6.
[74] Arnaboldi L, Guzzetta M, Pazzucconi F, Radaelli G, Paoletti R, Sirtori CR, Corsini A. Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. Pharmacol Res, 2007, 56(6): 503-8
[75] Massonnet B, Normand S, Moschitz R, et al. Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human866-70.
[84] Myeong-Ki Hong, MD, Duk-Woo Park, MD, Cheol-Whan Lee, MD, et al. Effects of Statin Treatments on Coronary Plaques Assessed by Volumetric Virtual Histology Intravascular Ultrasound Analysis. J Am Coll Cardiol Intv, 2009, 2:679-688,
[85] Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol, 2009; 49(7):838-47.
[86] Yu CM, Zhang Q, Lam L, et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 2007, 93(8):933-9.
[87] Kastelein JJP, Akdim F, Stroes ESG.et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia [J]. N Engl J Med,2008,358(14):1 431-443.
[88] Bowman L,Armitage J,Bulbulia R,et al. SEARCH Study Collaborative Group ,Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARC H) :characteristics of a randomized trail among 12 064 myocardial infarction surivors [J]. Am Heart J, 2007, 154( 5) :815-23, 823,el-6
[89]缺血性心脏病的命名及诊断标准国际心脏病学会和协会/世界卫生组织临床命名标准化联合专题组的联合报告.中华心血管病杂志,1981, 9(1): 75
[90]中华人民共和国卫生部.中药新药临床研究指导原则.中国医药学报,1987, 2( 6): 52,46
[91]张硕,宋衍芹,岳旺,等.益气通脉口服液治疗冠心病心绞痛的多中心随机双盲临床研究.中西结合学报,2007, 5(4):383-391
[92]冠心病心绞痛及心电图疗效判定标准(中西医结合治疗冠心病心绞痛及心律失常座谈会1979年9月上海) .中国药事,1987,1(2):71
[93] Kuo DH, Yeh CH, Shieh PC, Cheng KC, Chen FA, Cheng JT. Effect of shanzha, a Chinese herbal product, on obesity and dyslipidemia in hamsters receiving high-fat diet. J Ethnopharmacol, 2009, 124(3):544-50.
[94] Zhao HY, Wang WH. The effect of shanzha xiaozhi capsule on the blood lipid and the function of endothelial cells in patients with dislipide mia. Zhong Yao Cai, 2006, 29(6):629-31.
[95] Ren ZH, Tong YH, Xu W, Ma J, Chen Y. Tanshinone II A attenuates inflammatory res -pon ses of rats with myocardial infarction by reducing MCP-1 expression. Phytome -dicine. 2009 Oct 2. [Epub ahead of print] doi: 10.1016/ j.phy med .2009.08.010
[96] Fang ZY, Lin R, Yuan BX, Liu Y, Zhang H. Tanshinone IIA inhibits atherosclerotic plaque formation by down-regulating MMP-2 and MMP-9 expression in rabbits fed a high-fat diet. Life Sci, 2007, 81(17-18):1339-45.
[2]赵喜娟李振军.张荣新主任医师治疗冠心病心绞痛经验举隅[J].陕西中医学院学报2006,29(1):19
[3]梅岩,张明雪.从“阳微阴弦”治冠心病[J].中医药学刊,2006,24(4):683-684.
[4]李敬孝,韩超,焦赢君.从痰论治冠心病[J].长春中医药大学学报,2009,25(5):685-686
[5]林宝华.浅谈冠心病心绞痛从肝论治[J].福建中医药2006,37(3):34-35
[6]张明雪,常艳鹏,吴东宁等.论“气滞”在冠心病发病中的作用[J].世界中西医结合杂志,2009,4(7):486-487
[7]李成林,王庆高,朱智德.冠心病心绞痛中医证型与脑钠肽、C-反应蛋白和肌钙蛋白相关性研究[J].新中医,2008,40(7):32-33.
[8]黄永生.冠心病心绞痛临床诊治体会[J].长春中医学院学报,2005,21(1):16
[9]王振涛,韩丽华,朱照军等.孙建芝辨证冠心病经验[J].江苏中医药,2009,41(4):15-16
[10]王阶,邢雁伟,姚魁武,李军.冠心病心绞痛中医证候要素研究及临床应用[J].湖北中医学院学报,2009,11(3):3-5
[11]张浒,莫健平,林仕群.血府逐瘀汤加曲美他嗪治疗冠状动脉粥样硬化性心脏病心绞痛43例疗效分析[J].河北医药,2009,31(13):1663-1664
[12]张云.川芎嗪注射液治疗冠心病心绞痛疗效观察[J].中华中西医学杂志,2009,7(2):65-65
[13]陈琼莉.丹红注射液治疗老年性冠心病心绞痛56例疗效观察[J].中华实用中西医杂志2009,22(19):1521
[14]杨立群,李春瑜.活血化痰法治疗冠心病心绞痛[J].中国现代药物应用,2009,3(13):111-112
[15]齐双,刘东方.调脂汤治疗稳定性心绞痛临床观察.黑龙江中医药学报,2009,37(4)42-44
[16]谭奇,刘建和.益气活血法治疗冠心病心绞痛62例临床观察[J].中华临床医学研究杂志,2007,13(5):655-656
[17]唐善平.益气活血法对老年不稳定型心绞痛患者左室收缩功能的影响[J].中国中医急症学,2009,18(9):1403-1404
[18]史春远.益气活血方治疗冠心病60例[J].中国医学创新,2009,6(27):143
[19]刘金先.理气化瘀解毒法治疗冠心病106例[J].中医药临床杂志,2009,21(1):5
[20]颜君.疏肝理气发治疗冠心病心绞痛(附66例临床分析)[J].中外医疗,2009,12:113
[21]欧阳真理.益气温阳宣痹通络法治疗心绞痛60例[J].深圳中西医结合杂志,2006,16(1):49
[22]孟兆君,王海霞,房泽岱.宣痹通阳行气活血法治疗冠心病心绞痛临床观察[J].中国中医急症,2007,16(2):130-131
[23]施敖听.益气养阴法为主治疗冠心病56例[J].实用中医内科杂志,2005,19(2):159
[24]李景鹤.养阴益气活血方治疗冠心病[J].河南中医,2007,27(11):43
[25]卫生部.2007年中国卫生统计年鉴.北京中国医科协和大学出版社,2007
[26]卫生部心血管病防治研究中心.中国心血管病报告2007.中国大百科全书出版社,2007
[27] M Sawabe.et al. High lipoprotein(a) level promotes both coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases. Heart, 2009, 95:1997-2002
[28] Anna Bennet, PhD; Emanuele Di Angelantonio, MD, MSc; Sebhat Erqou, MD, M Ph il; et al. Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease . Arch Intern Med, 2008, 168(6):598-608.
[29] Erqou S, Kaptoge S, Perry PL, Di Angelantonio E Thompson A, White IR, et al. Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease,Stroke, and Nonvascular Mortality JAMA, 2009, 302(4):412- 423.
[30] Pia R. Kamstrup.et al. Pentanucleotide Repeat Polymorphism, Lipoprotein(a)Levels, and Risk of Ischemic Heart Disease. Journal of Clinical Endocrinology & Metabolism, 2008, 93: 3769-3776
[31] Rebecca J. Sharp.et al. Structural features of apolipoprotein B synthetic peptides that inhibitlipoprotein(a) assembly. Journal of Lipid Research,2004,45 : 2227-2234,
[32] Tsimikas, Sotirios. Witztum, Joseph.et al .The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Hyperlipidaemia and cardiovascular disease, 2008, 19( 4) :369-377
[33] Sotirios Tsimikas, M.D .et al. Oxidized Phospholipids. Lp(a) Lipoprotein, and Corona -ry Artery Disease . the New England Journal of Medicine, 2005, 353:46-57
[34] Robert Clarke, F.R.C.P., John F. Peden, Ph.D., Jemma C. Hopewell, Ph.D., Theodosios Kyriakou Ph.D. et.al. Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease, The NEW ENGLAND JOURANLofWEDICINE, 2009, 26, 361: 25182528.
[35] Mark W.et al. FeinbergTransforming Growth Factor-β1 Inhibition of Vascular Smo oth Muscle Cell Activation Is Mediated via Smad3.The Journal of Biological Chemis–try, 2004, 279: 16388-16393.
[36] Shirling Tsai. et al. TGF-βthrough Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation . Am J Physiol Heart Circ Physiol, 2009, 297:0363-6135
[37] William Discepolo.et al. Lipoprotein(a) and Thrombocytes: Potential Mechanisms Underlying Cardiovascular Risk. Pathophysiol Haemos Thromb,2006, 35:314-321
[38] Konrad Schmidt. et al.Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon. European Journal of Human Genetics, 2006, 14: 190–201.
[39] Erdembileg Anuurad.et al. High Levels of Inflammatory Biomarkers Are Associated with Increased Allele-Specific Apolipoprotein(a) Levels in African-Americans .The Journal of Clinical Endocrinology& Metabolism, 2008,93( 4) : 1482-1488
[40] Andrew C. Newby, Jason L. Johnson.et al. Genetic Strategies to Elucidate the Roles of Matrix Metalloproteinases in Atherosclerotic Plaque Growth andStability.Circulati -on Research, 2005, 97:958.
[41] Newby AC. et al. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atheros clerotic plaque rupture〔J〕. Physiol Rev,2005,85(1): 1-31
[42] Chow AK,Cena J,Schulz R. Acute actions and novel targets of matrix metallo pro teinases in the heart and vasculature〔J〕.Br J Pharmacol,2007,152(2):189-205.
[43] Kuge Y,Takai N,Ishino S,et al. Distribution profiles of membrane type-1 matrix metalloproteinase (MT1 , MMP) , matrix metalloproteinase(MMP-2) and cyclooxygenase-2 (COX-2) in rabbit atherosclerosis:comparison with plaque instability analysis〔J〕. Biol Pharm Bull, 2007, 30(9):1634-40.
[44] Eve Pearce, David-Alexandre Tregouet, Ann Samneg?rd, et al. Haplotype Effect of the Matrix Metalloproteinase-1 Gene on Risk of Myocardial Infarction. Circ. Res, 2005, 97: 1070-1076
[45] Manginas A , Bei E , Chaidaroglou A,et al. Peripheral levels of matrix metalloproteinase-9 , interleukin-6 , and C-reactive protein are elevated in patients with acute coronary syndromes: Correlations with serum troponinI〔J〕.Clin Cardiol, 2005, 28(4):182-6.
[46] KeitaItatsu, MotokoSasaki, JunpeiYamaguchi, et al. Cyclooxygenase-2 Is Involved in the Up- Regulation of Matrix Metalloproteinase-9 in Cholangiocarcinoma Induced by Tumor Necrosis Factor-α. Am J Pathol, 2009,174(3): 829–841.
[47] Zhiwei Wang, Dejuan Kong, Sanjeev Banerjee, et al. Down-regulation of Platelet-Derived Growth Factor-D Inhibits Cell Growth and Angiogenesis through Inactivation of Notch-1 and Nuclear Factor- B Signaling .Cancer Res, 2007, 67(23):11377–85
[48] John Lamar, Vandana Iyer,and C. Michael DiPersio. Integrinα3β1 potentiates TGFβ- mediated induction of MMP-9 in immortalized keratinocytes. Journal ofInvestigative Dermatology, 2008, 128: 575–586
[49] Caroline Demacq, Ana P. de Souza, Alcyone A. Machado, Raquel F. Gerlach and Jose E. Tanus-Santos. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clinica Chimica Acta, 2006, 365: 183-187
[50] Nicholas L. Mills, M.D., H?kan T?rnqvist, M.D., Manuel C. Gonzalez, M.D., et al. Ischemic and Thrombotic Effects of Dilute Diesel-Exhaust Inhalation in Men with Coronary Heart Disease. The New England Journal of Medicine,2007,357:1075-1082
[51] Amie K. Lund, JoAnn Lucero, SelitáLucas, Michael C. Madden, Jacob D. et al. Vehicular Emissions Induce Vascular MMP-9 Expression and Activity Associated With Endothelin-1–Mediated Pathways. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29:511
[52] Welsh P, Whincup PH, Papacosta O, Wannamethee SG, Lennon L, Thomson A, Rumley A, Lowe GD. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. Oxford Journals Medicine,2008, 101(10):785-91.
[53] Buralli S, Dini FL, Ballo P, et al. Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure. Am J Cardiol, 2010, 105(6):853-6.
[54] Deardorff R, Spinale FG. Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. Biomark Med, 2009, 3(5):513-523.
[55] Wald DS, Bestwick JP, Morton G, et al. Combining carotid intima-media thickness with carotid plaque on screening for coronary heart disease. Journal of Medical Screening, 2009, 16(3):155-9.
[56] Grewal J, Anand S, Islam S, Lonn E; SHARE and SHARE-AP Investigators Prevalence and predictors of subclinical atherosclerosisamong asymptomatic "low risk" individuals in a multiethnic population. Atherosclerosis, 2008 ,197(1): 435-42.
[57] Rohani M, Jogestrand T, Ekberg M, et al. Interrelation between the Extent of atherosclerosis in the thoracic aorta, carotidintima-media Thickness and the extent of coronary artery disease[J]. Atheroselerosis, 2005, 179(2): 311-316.
[58] Chien KL, Su TC, Jeng JS, et al. Carotid artery intima-media thickness, carotid plaque and coronary heart disease and stroke in Chinese. PLoS One, 2008,3(10): 34-35.
[59] Kwon TG, Kim KW, Park HW, Jeong JH, Kim KY, Bae JH. Prevalence and significance of carotid plaques in patients with coronary atherosclerosis. Korean Circ J, 2009, 39(8): 317-21.
[60] Strandberg TE, Pyorala K, Cook TJ, et al 4S Group. Mortality andIncidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) [J] Lancet , 2004, 364(9436):771-777.
[61] MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial [J]. Lancet, 2002, 3607-3622.
[62] Grundy SM, Cleeman J l, Merz CN, et al. National Heart,Lung,and blood Institut -e:American College of Cardiology Foundation:Ameri-can Heart Association. Implic-ations of recent clinical trials for theNational Cholesterol Edueation Program AdultTreatment PaneⅢguidelines[J]. Circulation, 2004,110(2):227-239.
[63] LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets(TNT) Investigato -rs . Intensive lipid lowering with atorvastatin in patients with stable coronary disease [J]. N Engl J Med, 2005, 352(14):1425-1435.
[64] Kolovou GD, Katerina A, Ioannis V, Cokkinos DV.Simvastatin: two decades in a circl -e. Cardiovasc Ther, 2008, 26(2): 166-78.
[65] Lo Prete AC, Dina CH, Azevedo CH, et al. In Vitro Simultaneous Transfer of Lipids to HDL in Coronary Artery Disease and in Statin Treatment. Lipids, 2009, 44: 917-924
[66] Saito Y.et al. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag, 2009, 5:921-36
[67] Barter PJ, Brandrup-Wognsen G, Palmer MK, Nocholls SJ. Effect of statins on HDL: a complex process unrelated to changes in LDL: Analysis of the VOYAGER Database. J Lipid Res, 2009, 5: 195-200
[68] Jia XW, Fu XH, Zhang J, et al. Inten -sive cholesterol lowering with statin improves the outcomes of percutaneous coronar -y intervention in patients with acute coronary syndrome. Chinese Medical Journal, 2009, 122(6):659-64
[69] Cakmak M, Tanriverdi H, Cakmak N, et al. Simvastatin may improve myocardial perfusion abnormality in slow coronary flow. Cardiology, 2008,110(1): 39-44
[70] Chan KC, Wang CJ, Ho HH, Chen HM, Huang CN.Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53. Pharmacol Res, 2008, 58(3-4): 247-56.
[71] Wada H, Abe M, Ono K, et al. Statins activate GATA-6 and induce differentiated vascular smooth muscle cells. Biochem Biophys Res Commun , 2008 ,374(4):731-6
[72] Park KW, Hwang KK, Cho HJ, et al. Simvastatin enhances endothelial differentiation of peripheral blood mononuclear cells in hypercholesterolemic patients and induces pro-angiogenic cytokine IL-8 secretion from monocytes. Clin Chim Acta, 2008, 388(1-2): 156-66.
[73] Obi C, Wysokinski W, Karnicki K, Owen WG, McBane RD 2nd. Inhibition of platelet -rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy. Arterioscler Thromb Vasc Biol,2009,29(9):1271-6.
[74] Arnaboldi L, Guzzetta M, Pazzucconi F, Radaelli G, Paoletti R, Sirtori CR, Corsini A. Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. Pharmacol Res, 2007, 56(6): 503-8
[75] Massonnet B, Normand S, Moschitz R, et al. Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human921-36
[67] Barter PJ, Brandrup-Wognsen G, Palmer MK, Nocholls SJ. Effect of statins on HDL: a complex process unrelated to changes in LDL: Analysis of the VOYAGER Database. J Lipid Res, 2009, 5: 195-200
[68] Jia XW, Fu XH, Zhang J, et al. Inten -sive cholesterol lowering with statin improves the outcomes of percutaneous coronar -y intervention in patients with acute coronary syndrome. Chinese Medical Journal, 2009, 122(6):659-64
[69] Cakmak M, Tanriverdi H, Cakmak N, et al. Simvastatin may improve myocardial perfusion abnormality in slow coronary flow. Cardiology, 2008,110(1): 39-44
[70] Chan KC, Wang CJ, Ho HH, Chen HM, Huang CN.Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53. Pharmacol Res, 2008, 58(3-4): 247-56.
[71] Wada H, Abe M, Ono K, et al. Statins activate GATA-6 and induce differentiated vascular smooth muscle cells. Biochem Biophys Res Commun , 2008 ,374(4):731-6
[72] Park KW, Hwang KK, Cho HJ, et al. Simvastatin enhances endothelial differentiation of peripheral blood mononuclear cells in hypercholesterolemic patients and induces pro-angiogenic cytokine IL-8 secretion from monocytes. Clin Chim Acta, 2008, 388(1-2): 156-66.
[73] Obi C, Wysokinski W, Karnicki K, Owen WG, McBane RD 2nd. Inhibition of platelet -rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy. Arterioscler Thromb Vasc Biol,2009,29(9):1271-6.
[74] Arnaboldi L, Guzzetta M, Pazzucconi F, Radaelli G, Paoletti R, Sirtori CR, Corsini A. Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. Pharmacol Res, 2007, 56(6): 503-8
[75] Massonnet B, Normand S, Moschitz R, et al. Pharmacological inhibitors of the mevalonate pathway activate pro-IL-1 processing and IL-1 release by human866-70.
[84] Myeong-Ki Hong, MD, Duk-Woo Park, MD, Cheol-Whan Lee, MD, et al. Effects of Statin Treatments on Coronary Plaques Assessed by Volumetric Virtual Histology Intravascular Ultrasound Analysis. J Am Coll Cardiol Intv, 2009, 2:679-688,
[85] Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol, 2009; 49(7):838-47.
[86] Yu CM, Zhang Q, Lam L, et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 2007, 93(8):933-9.
[87] Kastelein JJP, Akdim F, Stroes ESG.et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia [J]. N Engl J Med,2008,358(14):1 431-443.
[88] Bowman L,Armitage J,Bulbulia R,et al. SEARCH Study Collaborative Group ,Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARC H) :characteristics of a randomized trail among 12 064 myocardial infarction surivors [J]. Am Heart J, 2007, 154( 5) :815-23, 823,el-6
[89]缺血性心脏病的命名及诊断标准国际心脏病学会和协会/世界卫生组织临床命名标准化联合专题组的联合报告.中华心血管病杂志,1981, 9(1): 75
[90]中华人民共和国卫生部.中药新药临床研究指导原则.中国医药学报,1987, 2( 6): 52,46
[91]张硕,宋衍芹,岳旺,等.益气通脉口服液治疗冠心病心绞痛的多中心随机双盲临床研究.中西结合学报,2007, 5(4):383-391
[92]冠心病心绞痛及心电图疗效判定标准(中西医结合治疗冠心病心绞痛及心律失常座谈会1979年9月上海) .中国药事,1987,1(2):71
[93] Kuo DH, Yeh CH, Shieh PC, Cheng KC, Chen FA, Cheng JT. Effect of shanzha, a Chinese herbal product, on obesity and dyslipidemia in hamsters receiving high-fat diet. J Ethnopharmacol, 2009, 124(3):544-50.
[94] Zhao HY, Wang WH. The effect of shanzha xiaozhi capsule on the blood lipid and the function of endothelial cells in patients with dislipide mia. Zhong Yao Cai, 2006, 29(6):629-31.
[95] Ren ZH, Tong YH, Xu W, Ma J, Chen Y. Tanshinone II A attenuates inflammatory res -pon ses of rats with myocardial infarction by reducing MCP-1 expression. Phytome -dicine. 2009 Oct 2. [Epub ahead of print] doi: 10.1016/ j.phy med .2009.08.010
[96] Fang ZY, Lin R, Yuan BX, Liu Y, Zhang H. Tanshinone IIA inhibits atherosclerotic plaque formation by down-regulating MMP-2 and MMP-9 expression in rabbits fed a high-fat diet. Life Sci, 2007, 81(17-18):1339-45.